Role of Dydrogesterone for Luteal Phase Support in Assisted Reproduction.

Dydrogesterone Fertilization in vitro Luteal phase Progesterone

Journal

Reproductive sciences (Thousand Oaks, Calif.)

ISSN: 1933-7205

Titre abrégé: Reprod Sci

Pays: United States

ID NLM: 101291249

Informations de publication

Date de publication:
24 Jul 2023

Historique:

received: 14 12 2022

accepted: 10 07 2023

medline: 25 7 2023

pubmed: 25 7 2023

entrez: 24 7 2023

Statut: aheadofprint

Résumé

Clinical outcomes of in vitro fertilization (IVF) have significantly improved over the years with the advent of the frozen-thawed embryo transfer (FET) technique. Ovarian hyperstimulation during IVF cycles causes luteal phase deficiency, a condition of insufficient progesterone. Intramuscular or vaginal progesterone and dydrogesterone are commonly used for luteal phase support in FET. Oral dydrogesterone has a higher bioavailability than progesterone and has high specificity for progesterone receptors. Though micronized vaginal progesterone has been the preferred option, recent data suggest that oral dydrogesterone might be an alternative therapeutic option for luteal phase support to improve clinical outcomes of IVF cycles. Dydrogesterone has a good safety profile and is well tolerated. Its efficacy has been evaluated in several clinical studies and demonstrated to be non-inferior to micronized vaginal progesterone in large-scale clinical trials. Oral dydrogesterone may potentially become a preferred drug for luteal phase support in millions of women undergoing IVF.

Identifiants

DOI: 10.1007/s43032-023-01302-z PMID: 37488405

pubmed: 37488405

doi: 10.1007/s43032-023-01302-z

pii: 10.1007/s43032-023-01302-z

doi:

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

Informations de copyright

Références

Taraborrelli S. Physiology, production and action of progesterone. Acta Obstet Gynecol Scand. 2015;94(Suppl 161):8–16. https://doi.org/10.1111/aogs.12771 .

doi: 10.1111/aogs.12771 pubmed: 26358238

Griesinger G, Tournaye H, Macklon N, Petraglia F, Arck P, Blockeel C, et al. Dydrogesterone: pharmacological profile and mechanism of action as luteal phase support in assisted reproduction. Reprod Biomed Online. 2019;38(2):249–59. https://doi.org/10.1016/j.rbmo.2018.11.017 .

doi: 10.1016/j.rbmo.2018.11.017 pubmed: 30595525

Carp HJA. Progestogens and pregnancy loss. Climacteric. 2018;21(4):380–4. https://doi.org/10.1080/13697137.2018.1436166 .

doi: 10.1080/13697137.2018.1436166 pubmed: 29565684

Csapo AI, Pulkkinen M. Indispensability of the human corpus luteum in the maintenance of early pregnancy. Luteectomy evidence Obstet Gynecol Surv. 1978;33(2):69–81. https://doi.org/10.1097/00006254-197802000-00001 .

doi: 10.1097/00006254-197802000-00001 pubmed: 341008

Kolibianakis EM, Bourgain C, Platteau P, Albano C, Van Steirteghem AC, Devroey P. Abnormal endometrial development occurs during the luteal phase of nonsupplemented donor cycles treated with recombinant follicle-stimulating hormone and gonadotropin-releasing hormone antagonists. Fertil Steril. 2003;80(2):464–6. https://doi.org/10.1016/s0015-0282(03)00663-0 .

doi: 10.1016/s0015-0282(03)00663-0 pubmed: 12909519

The Practice Committee of the American Society for Reproductive Medicine. The clinical relevance of luteal phase deficiency: a committee opinion. Fertil Steril. 2012;98(5):1112–7. https://doi.org/10.1016/j.fertnstert.2012.06.050 .

van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M. 2015 Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev. 2015;7:CD009154. https://doi.org/10.1002/14651858.CD009154.pub3 .

doi: 10.1002/14651858.CD009154.pub3

The Practice Committee of the American Society for Reproductive Medicine. Progesterone supplementation during the luteal phase and in early pregnancy in the treatment of infertility: an educational bulletin. Fertil Steril. 2008;89(4):789–92. https://doi.org/10.1016/j.fertnstert.2008.02.012

Griesinger G, Blockeel C, Tournaye H. Oral dydrogesterone for luteal phase support in fresh in vitro fertilization cycles: a new standard? Fertil Steril. 2018;109(5):756–62. https://doi.org/10.1016/j.fertnstert.2018.03.034 .

doi: 10.1016/j.fertnstert.2018.03.034 pubmed: 29778368

Tournaye H, Sukhikh GT, Kahler E, Griesinger G. A Phase III randomized controlled trial comparing the efficacy, safety and tolerability of oral dydrogesterone versus micronized vaginal progesterone for luteal support in in vitro fertilization. Hum Reprod. 2017;32(10):2152. https://doi.org/10.1093/humrep/dex266 .

doi: 10.1093/humrep/dex266 pubmed: 28938733 pmcid: 6790500

Griesinger G, Blockeel C, Sukhikh GT, Patki A, Dhorepatil B, Yang DZ, et al. Oral dydrogesterone versus intravaginal micronized progesterone gel for luteal phase support in IVF: a randomized clinical trial. Hum Reprod. 2018;33(12):2212–21. https://doi.org/10.1093/humrep/dey306 .

doi: 10.1093/humrep/dey306 pubmed: 30304457 pmcid: 6238366

Chakravarty BN, Shirazee HH, Dam P, Goswami SK, Chatterjee R, Ghosh S. Oral dydrogesterone versus intravaginal micronised progesterone as luteal phase support in assisted reproductive technology (ART) cycles: results of a randomised study. J Steroid Biochem Mol Biol. 2005;97(5):416–20. https://doi.org/10.1016/j.jsbmb.2005.08.012 .

doi: 10.1016/j.jsbmb.2005.08.012 pubmed: 16213136

Groenewoud ER, Cantineau AE, Kollen BJ, Macklon NS, Cohlen BJ. What is the optimal means of preparing the endometrium in frozen-thawed embryo transfer cycles? A systematic review and meta-analysis. Hum Reprod Update. 2013;19(5):458–70. https://doi.org/10.1093/humupd/dmt030 .

doi: 10.1093/humupd/dmt030 pubmed: 23820515

RezazadehValojerdi M, Eftekhari-Yazdi P, Karimian L, Hassani F, Movaghar B. Vitrification versus slow freezing gives excellent survival, post warming embryo morphology and pregnancy outcomes for human cleaved embryos. J Assist Reprod Genet. 2009;26(6):347–54. https://doi.org/10.1007/s10815-009-9318-6 .

doi: 10.1007/s10815-009-9318-6

Noble M, Child T. The role of frozen–thawed embryo replacement cyclesin assisted conception. Obstet Gynaecol. 2020;22:57–68. https://doi.org/10.1111/tog.12630 .

doi: 10.1111/tog.12630

Fauser BC, Devroey P. Reproductive biology and IVF: ovarian stimulation and luteal phase consequences. Trends Endocrinol Metab. 2003;14(5):236–42. https://doi.org/10.1016/s1043-2760(03)00075-4 .

doi: 10.1016/s1043-2760(03)00075-4 pubmed: 12826330

Palomba S, Santagni S, La Sala GB. Progesterone administration for luteal phase deficiency in human reproduction: an old or new issue? J Ovarian Res. 2015;8:77. https://doi.org/10.1186/s13048-015-0205-8 .

doi: 10.1186/s13048-015-0205-8 pubmed: 26585269 pmcid: 4653859

Chau LTM, Tu DK, Lehert P, Dung DV, Thanh LQ, Tuan VM. Clinical pregnancy following GnRH agonist administration in the luteal phase of fresh or frozen assisted reproductive technology (ART) cycles: Systematic review and meta-analysis. Eur J Obstet Gynecol Reprod Biol X. 2019;3:100046. https://doi.org/10.1016/j.eurox.2019.100046 .

doi: 10.1016/j.eurox.2019.100046 pubmed: 31403130 pmcid: 6687475

Stimpfel M, Vrtacnik-Bokal E, Pozlep B, Virant-Klun I. Comparison of GnRH agonist, GnRH antagonist, and GnRH antagonist mild protocol of controlled ovarian hyperstimulation in good prognosis patients. Int J Endocrinol. 2015;2015:385049. https://doi.org/10.1155/2015/385049 .

doi: 10.1155/2015/385049 pubmed: 25866508 pmcid: 4381687

Yding Andersen C, Vilbour AK. Improving the luteal phase after ovarian stimulation: reviewing new options. Reprod Biomed Online. 2014;28(5):552–9. https://doi.org/10.1016/j.rbmo.2014.01.012 .

doi: 10.1016/j.rbmo.2014.01.012 pubmed: 24656557

Banker M, Garcia-Velasco JA. Revisiting ovarian hyper stimulation syndrome: Towards OHSS free clinic. J Hum Reprod Sci. 2015;8(1):13–7. https://doi.org/10.4103/0974-1208.153120 .

doi: 10.4103/0974-1208.153120 pubmed: 25838743 pmcid: 4381376

Scott R, Navot D, Liu HC, Rosenwaks Z. A human in vivo model for the luteoplacental shift. Fertil Steril. 1991;56(3):481–4. https://doi.org/10.1016/s0015-0282(16)54544-0 .

doi: 10.1016/s0015-0282(16)54544-0 pubmed: 1894025

Mackens S, Santos-Ribeiro S, van de Vijver A, Racca A, Van Landuyt L, Tournaye H, et al. Frozen embryo transfer: a review on the optimal endometrial preparation and timing. Hum Reprod. 2017;32(11):2234–42. https://doi.org/10.1093/humrep/dex285 .

doi: 10.1093/humrep/dex285 pubmed: 29025055

Kawachiya S, Bodri D, Hirosawa T, Yao Serna J, Kuwahara A, Irahara M. Endogenous progesterone levels could predict reproductive outcome in frozen embryo replacement cycles supplemented with synthetic progestogens: A retrospective cohort study. Reprod Med Biol. 2019;18(1):91–6. https://doi.org/10.1002/rmb2.12254 .

doi: 10.1002/rmb2.12254 pubmed: 30655726

Yang R, Chi H, Chen L, Li R, Liu P, Qiao J. Impact of different luteal support methods on clinical outcomes of frozen-thawed embryo transfer cycles. Zhonghua Yi Xue Za Zhi. 2014;94(41):3256–8.

pubmed: 25604229

Guo W, Chen X, Ye D, He Y, Li P, Niu J, et al. Effects of oral dydrogesterone on clinical outcomes of frozen-thawed embryo transfer cycles. Nan Fang Yi Ke Da Xue Xue Bao. 2013;33(6):861–5.

pubmed: 23803198

Zarei A, Sohail P, Parsanezhad ME, Alborzi S, Samsami A, Azizi M. Comparison of four protocols for luteal phase support in frozen-thawed Embryo transfer cycles: a randomized clinical trial. Arch Gynecol Obstet. 2017;295(1):239–46. https://doi.org/10.1007/s00404-016-4217-4 .

doi: 10.1007/s00404-016-4217-4 pubmed: 27761732

Liu XR, Mu HQ, Shi Q, Xiao XQ, Qi HB. The optimal duration of progesterone supplementation in pregnant women after IVF/ICSI: a meta-analysis. Reprod Biol Endocrinol. 2012;10:107. https://doi.org/10.1186/1477-7827-10-107 .

doi: 10.1186/1477-7827-10-107 pubmed: 23237065 pmcid: 3551800

The Practice Committee of the Society for Assisted Reproductive Technology, Practice Committee of the American Society for Reproductive Medicine. Guidelines on number of embryos transferred. Fertil Steril. 2008;90(5 Suppl):S163–4. https://doi.org/10.1016/j.fertnstert.2008.08.053 .

National Collaborating Centre for Women’s and Children’s Health (UK). Fertility: Assessment and Treatment for People with Fertility Problems. London (UK): RCOG Press. 2004.

van der Linden M, Buckingham K, Farquhar C, Kremer JA, Metwally M. Luteal phase support for assisted reproduction cycles. Cochrane Database Syst Rev. 2011;10:CD009154. https://doi.org/10.1002/14651858.CD009154.pub2 .

doi: 10.1002/14651858.CD009154.pub2

Stimulation EGGOO, Bosch E, Broer S, Griesinger G, Grynberg M, Humaidan P, et al. Erratum: ESHRE guideline: ovarian stimulation for IVF/ICSI. Hum Reprod Open. 2020;2020(4):hoaa067. https://doi.org/10.1093/hropen/hoaa067 .

doi: 10.1093/hropen/hoaa067

Barbosa MW, Silva LR, Navarro PA, Ferriani RA, Nastri CO, Martins WP. Dydrogesterone vs progesterone for luteal-phase support: systematic review and meta-analysis of randomized controlled trials. Ultrasound Obstet Gynecol. 2016;48(2):161–70. https://doi.org/10.1002/uog.15814 .

doi: 10.1002/uog.15814 pubmed: 26577241

Chakravarty BN, Dam P, Goswami SK, Ghosh S, Chattopadhyay R. Oral dydrogesterone versus vaginal micronised progesterone as luteal phase support in ART cycles–evaluation based on correction of hormone profile and clinical outcome. Human Reprod. 2005;20(suppl_1):i133–41.

Patki A, Pawar VC. Modulating fertility outcome in assisted reproductive technologies by the use of dydrogesterone. Gynecol Endocrinol. 2007;23(Suppl 1):68–72. https://doi.org/10.1080/09513590701584857 .

doi: 10.1080/09513590701584857 pubmed: 17943542

Ganesh A, Chakravorty N, Mukherjee R, Goswami S, Chaudhury K, Chakravarty B. Comparison of oral dydrogestrone with progesterone gel and micronized progesterone for luteal support in 1,373 women undergoing in vitro fertilization: a randomized clinical study. Fertil Steril. 2011;95(6):1961–5. https://doi.org/10.1016/j.fertnstert.2011.01.148 .

doi: 10.1016/j.fertnstert.2011.01.148 pubmed: 21333984

Saharkhiz N, Zamaniyan M, Salehpour S, Zadehmodarres S, Hoseini S, Cheraghi L, et al. A comparative study of dydrogesterone and micronized progesterone for luteal phase support during in vitro fertilization (IVF) cycles. Gynecol Endocrinol. 2016;32(3):213–7. https://doi.org/10.3109/09513590.2015.1110136 .

doi: 10.3109/09513590.2015.1110136 pubmed: 26486011

Salehpour S, Tamimi M, Saharkhiz N. Comparison of oral dydrogesterone with suppository vaginal progesterone for luteal-phase support in in vitro fertilization (IVF): A randomized clinical trial. Iran J Reprod Med. 2013;11(11):913–8.

pubmed: 24639716 pmcid: 3941387

Tomic V, Tomic J, Klaic DZ, Kasum M, Kuna K. Oral dydrogesterone versus vaginal progesterone gel in the luteal phase support: randomized controlled trial. Eur J Obstet Gynecol Reprod Biol. 2015;186:49–53. https://doi.org/10.1016/j.ejogrb.2014.11.002 .

doi: 10.1016/j.ejogrb.2014.11.002 pubmed: 25622239

Pabuçcu E, Pabuçcu R, Gürgan T, Tavmergen E. Luteal phase support in fresh and frozen embryo transfer cycles. J Gynecol Obstet Hum Reprod. 2020;49(10):101838. https://doi.org/10.1016/j.jogoh.2020.101838 .

Wei D, Liu JY, Sun Y, Shi Y, Zhang B, Liu JQ, et al. Frozen versus fresh single blastocyst transfer in ovulatory women: a multicentre, randomised controlled trial. Lancet. 2019;393(10178):1310–8. https://doi.org/10.1016/S0140-6736(18)32843-5 .

doi: 10.1016/S0140-6736(18)32843-5 pubmed: 30827784

Pabuccu E, Kovanci E, Israfilova G, Tulek F, Demirel C, Pabuccu R. Oral, vaginal or intramuscular progesterone in programmed frozen embryo transfer cycles: a pilot randomized controlled trial. Reprod Biomed Online. 2022;45(6):1145–51. https://doi.org/10.1016/j.rbmo.2022.06.027 .

doi: 10.1016/j.rbmo.2022.06.027 pubmed: 36153226

Massin N, Pietin-Vialle C, Pasquier M, Heluin G, Haddad B, Bry-Gauillard H. How to implement in real-life settings the results of meta analysis? Example of dydrogesterone as luteal phase support after fresh embryo transfer in IVF procedure. Hum Reprod. 2016;31(suppl_1):i447. https://doi.org/10.1093/humrep/31.Supplement_1.1 .

Rashidi BH, Gorginzadeh M, Aalipour S, Sills ES. Age related endocrine patterns observed in polycystic ovary syndrome patients vs. ovulatory controls: descriptive data from a university based infertility center. Arch Endocrinol Metab. 2016;60(5):486–91. https://doi.org/10.1590/2359-3997000000215 .

doi: 10.1590/2359-3997000000215 pubmed: 27737330 pmcid: 10118636

Atzmon Y, Aslih N, Estrada D, Bilgory A, Ellenbogen A, Shalom-Paz E. Comparable Outcomes Using Oral Dydrogesterone Vs. Micronized Vaginal Progesterone in Frozen Embryo Transfer: a Retrospective Cohort Study. Reprod Sci. 2021;28(7):1874–81. https://doi.org/10.1007/s43032-020-00376-3 .

doi: 10.1007/s43032-020-00376-3 pubmed: 33140324

Ozer G, Yuksel B, YucelCicek OS, Kahraman S. Oral dydrogesterone vs. micronized vaginal progesterone gel for luteal phase support in frozen-thawed single blastocyst transfer in good prognosis patients. J Gynecol Obstet Hum Reprod. 2021;50(5):102030. https://doi.org/10.1016/j.jogoh.2020.102030 .

doi: 10.1016/j.jogoh.2020.102030 pubmed: 33271319

Patki A, Pai H, Shah D, Malik S, Rao K. Evaluating the role of oral dydrogesterone for luteal-phase support in women undergoing frozen embryo transfer: Systematic review with meta-analysis. J Fertil In vitro IVF Worldw Reprod Med Genet Stem Cell Biol. 2023;11:295.

Vuong LN, Pham TD, Le KTQ, Ly TT, Le HL, Nguyen DTN, et al. Micronized progesterone plus dydrogesterone versus micronized progesterone alone for luteal phase support in frozen-thawed cycles (MIDRONE): a prospective cohort study. Hum Reprod. 2021;36(7):1821–31. https://doi.org/10.1093/humrep/deab093 .

doi: 10.1093/humrep/deab093 pubmed: 33930124

Xu H, Zhang XQ, Zhu XL, Weng HN, Xu LQ, Huang L, et al. Comparison of vaginal progesterone gel combined with oral dydrogesterone versus intramuscular progesterone for luteal support in hormone replacement therapy-frozen embryo transfer cycle. J Gynecol Obstet Hum Reprod. 2021;50(7):102110. https://doi.org/10.1016/j.jogoh.2021.102110 .

doi: 10.1016/j.jogoh.2021.102110 pubmed: 33727207

Vidal A, Dhakal C, Werth N, Weiss JM, Lehnick D, Schwartz ASK. Supplementary dydrogesterone is beneficial as luteal phase support in artificial frozen-thawed embryo transfer cycles compared to micronized progesterone alone. Front Endocrinol (Lausanne). 2023;13(14):1128564. https://doi.org/10.3389/fendo.2023.1128564 .

doi: 10.3389/fendo.2023.1128564

Stanczyk FZ, Hapgood JP, Winer S, Mishell DR Jr. Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects. Endocr Rev. 2013;34(2):171–208. https://doi.org/10.1210/er.2012-1008 .

doi: 10.1210/er.2012-1008 pubmed: 23238854

Paulson RJ, Collins MG, Yankov VI. Progesterone pharmacokinetics and pharmacodynamics with 3 dosages and 2 regimens of an effervescent micronized progesterone vaginal insert. J Clin Endocrinol Metab. 2014;99(11):4241–9. https://doi.org/10.1210/jc.2013-3937 .

doi: 10.1210/jc.2013-3937 pubmed: 24606090

Schindler AE, Campagnoli C, Druckmann R, Huber J, Pasqualini JR, Schweppe KW, et al. Classification and pharmacology of progestins. Maturitas. 2003;46(Suppl 1):S7–16. https://doi.org/10.1016/j.maturitas.2003.09.014 .

doi: 10.1016/j.maturitas.2003.09.014 pubmed: 14670641

Daughton CG, Ruhoy IS. Lower-dose prescribing: minimizing “side effects” of pharmaceuticals on society and the environment. Sci Total Environ. 2013;443:324–37. https://doi.org/10.1016/j.scitotenv.2012.10.092 .

doi: 10.1016/j.scitotenv.2012.10.092 pubmed: 23201698

Ghabril M, Chalasani N, Bjornsson E. Drug-induced liver injury: a clinical update. Curr Opin Gastroenterol. 2010;26(3):222–6. https://doi.org/10.1097/MOG.0b013e3283383c7c .

doi: 10.1097/MOG.0b013e3283383c7c pubmed: 20186054 pmcid: 3156474

Kuhl H. Pharmacology of estrogens and progestogens: influence of different routes of administration. Climacteric. 2005;8(Suppl 1):3–63. https://doi.org/10.1080/13697130500148875 .

doi: 10.1080/13697130500148875 pubmed: 16112947

Rizner TL, Brozic P, Doucette C, Turek-Etienne T, Muller-Vieira U, Sonneveld E, et al. Selectivity and potency of the retroprogesterone dydrogesterone in vitro. Steroids. 2011;76(6):607–15. https://doi.org/10.1016/j.steroids.2011.02.043 .

doi: 10.1016/j.steroids.2011.02.043 pubmed: 21376746

Raghupathy R, Szekeres-Bartho J. Progesterone: a unique hormone with immunomodulatory roles in pregnancy. Int J Mol Sci. 2022;23(3):1333. https://doi.org/10.3390/ijms23031333

Netter A, Mancini J, Buffat C, Agostini A, Perrin J, Courbiere B. Do early luteal serum progesterone levels predict the reproductive outcomes in IVF with oral dydrogesterone for luteal phase support? PLoS One. 2019;14(7):e0220450. https://doi.org/10.1371/journal.pone.0220450 .

doi: 10.1371/journal.pone.0220450 pubmed: 31361764 pmcid: 6667136

El-Zibdeh MY, Yousef LT. Dydrogesterone support in threatened miscarriage. Maturitas. 2009;65(Suppl 1):S43–6. https://doi.org/10.1016/j.maturitas.2009.11.013 .

doi: 10.1016/j.maturitas.2009.11.013 pubmed: 20007011

Pandian RU. Dydrogesterone in threatened miscarriage: a Malaysian experience. Maturitas. 2009;65(Suppl 1):S47-50. https://doi.org/10.1016/j.maturitas.2009.11.016 .

doi: 10.1016/j.maturitas.2009.11.016 pubmed: 20005647

Ehrenskjold ML, Bondo B, Weile F. Treatment of threatened abortion with dydrogesterone. Ugeskr Laeger. 1967;129(50):1678–9.

pubmed: 5889245

Misto A. Experiences with 6-dehydro-retroprogesterone int the treatment of placental insufficiency. Ann Ostet Ginecol Med Perinat. 1967;89(2):102–12.

pubmed: 5601176

Vincze E, Molnár B, Földesi I, Pál A. Treatment possibilities for threatened abortion using progesterone and progesterone-type drugs. Magyar Noorvosok Lapja. 2006;69:281–4.

El-Zibdeh MY. Dydrogesterone in the reduction of recurrent spontaneous abortion. J Steroid Biochem Mol Biol. 2005;97(5):431–4. https://doi.org/10.1016/j.jsbmb.2005.08.007 .

doi: 10.1016/j.jsbmb.2005.08.007 pubmed: 16253504

Zaqout M, Aslem E, Abuqamar M, Abughazza O, Panzer J, De Wolf D. The Impact of Oral Intake of Dydrogesterone on Fetal Heart Development During Early Pregnancy. Pediatr Cardiol. 2015;36(7):1483–8. https://doi.org/10.1007/s00246-015-1190-9 .

doi: 10.1007/s00246-015-1190-9 pubmed: 25972284

Koren G, Gilboa D, Katz R. Expression of Concern to: Fetal Safety of Dydrogesterone Exposure in the First Trimester of Pregnancy. Clin Drug Investig. 2020;40(7):681. https://doi.org/10.1007/s40261-019-00884-4 .

doi: 10.1007/s40261-019-00884-4 pubmed: 31916053

Katalinic A, Shulman LP, Strauss JF, Garcia-Velasco JA, van den Anker JN. A critical appraisal of safety data on dydrogesterone for the support of early pregnancy: a scoping review and meta-analysis. Reprod Biomed Online. 2022;45(2):365–73. https://doi.org/10.1016/j.rbmo.2022.03.032 .

doi: 10.1016/j.rbmo.2022.03.032 pubmed: 35644880